VRX Financial Facts
Income from continuing operations attributable to Valeant: 0.39Less: Net income attributable to noncontrolling interest: 1K
See Full Income Statement
Accumulated deficit: -573.77M
Other assets: 22.83M
See Full Balance Sheet
Earnings History for Valeant Pharmaceuticals International (VRX)
|
Expand Research on VRX
| Next EPS Date | 8/1/13 *Est. | EPS Growth Rate | +31.3% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +1,215.5% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | +1.5% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
5/2/13  |
 |
Q113 | $1.30 | N/A | N/A | $1.07B | $1.04B | N/A / N/A |  |
+6.1% | Details |
| 2/28/13 |
|
Q412 | $1.34 | N/A | N/A | $946.67M | $654.17M | N/A / N/A | |
+17.1% | Details |
| 11/2/12 |
|
Q312 | $1.15 | N/A | N/A | $884.1M | $600.6M | N/A / N/A | = | +37.7% | Details |
| 8/2/12 |
|
Q212 | $1.01 | N/A | N/A | $820.1M | $822.7M | N/A / N/A | = | +66.7% | Details |
| 5/3/12 | Q112 | $0.99 | $0.02 | +$0.97 | N/A | N/A | $1.01 / $853.98M | = | +38.5% | Details | |
| 2/27/12 | Q411 | $0.94 | $0.84 | +$0.10 | $688.4M | $514.56M | N/A / N/A | = | +63.1% | Details | |
| 8/4/11 |
|
Q211 | $0.73 | N/A | N/A | $609M | $297.08M | N/A / N/A | |
+49.6% | Details |
| 5/9/11 |
Q111 | $0.02 | N/A | N/A | $565M | $297.08M | N/A / N/A | |
+56.3% | Details |
